139 related articles for article (PubMed ID: 37598478)
41. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
42. The IL-2A receptor pathway and its role in lymphocyte differentiation and function.
Li Y; Li X; Geng X; Zhao H
Cytokine Growth Factor Rev; 2022 Oct; 67():66-79. PubMed ID: 35803834
[TBL] [Abstract][Full Text] [Related]
43. Correlation between HPV-negative cervical lesions and cervical microenvironment.
Zheng JJ; Miao JR; Wu Q; Yu CX; Mu L; Song JH
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):855-861. PubMed ID: 33218401
[TBL] [Abstract][Full Text] [Related]
44. IL-2 enhances cervical cancer cells proliferation and JAK3/STAT5 phosphorylation at low doses, while at high doses IL-2 has opposite effects.
Valle-Mendiola A; Weiss-Steider B; Rocha-Zavaleta L; Soto-Cruz I
Cancer Invest; 2014 May; 32(4):115-25. PubMed ID: 24548303
[TBL] [Abstract][Full Text] [Related]
45. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
[TBL] [Abstract][Full Text] [Related]
46. Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer.
Zhang C; Gu L; Xiao J; Jin F
BMC Cancer; 2023 Jul; 23(1):684. PubMed ID: 37474926
[TBL] [Abstract][Full Text] [Related]
47. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
48. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
[TBL] [Abstract][Full Text] [Related]
49. Extracellular vesicular Wnt7b mediates HPV E6-induced cervical cancer angiogenesis by activating the β-catenin signaling pathway.
Qiu JJ; Sun SG; Tang XY; Lin YY; Hua KQ
J Exp Clin Cancer Res; 2020 Nov; 39(1):260. PubMed ID: 33234148
[TBL] [Abstract][Full Text] [Related]
50. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma.
Chen Z; Dong D; Zhu Y; Pang N; Ding J
FASEB J; 2021 Mar; 35(3):e21401. PubMed ID: 33559190
[TBL] [Abstract][Full Text] [Related]
51. IL-22 Signaling in the Tumor Microenvironment.
Jiang R; Sun B
Adv Exp Med Biol; 2021; 1290():81-88. PubMed ID: 33559856
[TBL] [Abstract][Full Text] [Related]
52. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NFκB-IL-6 signalling axis.
Morgan EL; Macdonald A
PLoS Pathog; 2019 Jun; 15(6):e1007835. PubMed ID: 31226168
[TBL] [Abstract][Full Text] [Related]
53. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
54. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.
Sabaawy HE; Ryan BM; Khiabanian H; Pine SR
Carcinogenesis; 2021 Dec; 42(12):1411-1419. PubMed ID: 34415330
[TBL] [Abstract][Full Text] [Related]
55. IL-10 expression is regulated by HPV E2 protein in cervical cancer cells.
Bermúdez-Morales VH; Peralta-Zaragoza O; Alcocer-González JM; Moreno J; Madrid-Marina V
Mol Med Rep; 2011; 4(2):369-75. PubMed ID: 21468579
[TBL] [Abstract][Full Text] [Related]
56. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT.
Tsuji-Takayama K; Suzuki M; Yamamoto M; Harashima A; Okochi A; Otani T; Inoue T; Sugimoto A; Motoda R; Yamasaki F; Nakamura S; Kibata M
Exp Hematol; 2008 Feb; 36(2):181-92. PubMed ID: 18023521
[TBL] [Abstract][Full Text] [Related]
57. Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade.
Miri SM; Pourhossein B; Hosseini SY; Keshavarz M; Shahmahmoodi S; Zolfaghari MR; Mohebbi SR; Gorji A; Ghaemi A
Virol J; 2022 Jun; 19(1):106. PubMed ID: 35752792
[TBL] [Abstract][Full Text] [Related]
58. Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission.
Taylor JM; Brown M; Nejmeddine M; Kim KJ; Ratner L; Lairmore M; Nicot C
J Virol; 2009 Nov; 83(22):11467-76. PubMed ID: 19726513
[TBL] [Abstract][Full Text] [Related]
59. Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer.
Liu X; Ni G; Zhang P; Li H; Li J; Cavallazzi Sebold B; Wu X; Chen G; Yuan S; Wang T
J Exp Clin Cancer Res; 2023 Jan; 42(1):28. PubMed ID: 36683048
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach.
Aliyu M; Zohora FT; Anka AU; Ali K; Maleknia S; Saffarioun M; Azizi G
Int Immunopharmacol; 2022 Oct; 111():109130. PubMed ID: 35969896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
